Top Wall Street Analysts Make Calls

Wall Street’s most talked-about, market-moving research requests are now in one place. Here are today’s findings from The Fly that investors need to know.

Top 5 upgrades:

• Piper Sandler has been upgraded Crispy cream Following last week’s announcement regarding a national partnership with McDonald’s (MCD), (DNUT) was changed from Neutral to Overweight and the price target was raised from $14 to $20. Analysts say the partnership is a “game changer” for the business and expect the story around Krispy Kreme to start to improve from here.

• Wells Fargo gets a double upgrade Cinemark (CNK) Increased price target from $13 to $23 and changed from underweight to overweight. The company says, “Movies are back!”

• Mones Crespi has been upgraded american express (AXP) Buy from Neutral with a price target of $245. The analyst likes the stock’s pricing after yesterday’s sell-off in the lead-up to its first-quarter earnings release.

• Oppenheimer has been upgraded angiodynamics (ANGO) has an Outperform rating with a price target of $12, following the company’s AlphaVac’s earlier-than-expected FDA approval on Thursday for an expanded indication to treat pulmonary embolism.

• Rosenblatt has been upgraded snowflake (SNOW) Buy from Neutral with a price target of $185. Analysts returning from a customer event in Toronto encouraged that broad customer interest in the Snowflake platform and the growing ecosystem around the company “remains very healthy.”

Top 5 downgrades:

• Wells Fargo downgraded Altis USA (ATUS) From equal weight to underweight, price target lowered by $1 from $2. The analyst believes the cable movement remains difficult as Altice USA is “in the crosshairs.”

• Downgrade of Wolfe Research shockwave medical (SWAV) From outperform to peer perform without a price target. The possibility of an acquisition by Johnson & Johnson (JNJ) is “realistic,” but Shockwave’s risk/return profile is currently unfavorable at around $320 per share, analysts told investors in a research note. Told.

• BofA Downgrade Kimco Realty (KIM) Price target changed from $24 to $20 and changed from Buy to Neutral. The firm removed Kimco from its analysts’ top picks list, and BofA left its annual NYC Retail REIT Executive Summit last week with new positives from several retail REITs, but Kimco remains ” Unfortunately, I can’t say the same thing.” .

• A trusted person has been demoted. scotts miracle gro (SMG) Increased price target from $65 to $75 and changed from buy to hold. With the company’s stock currently trading at 21 times estimated fiscal year 2025 earnings, the company believes much of the near-term positive news is reflected in Scotts Miracle-Gro’s valuation.

• City downgraded plug power (PLUG) has a Neutral to Sell rating with a price target of $3.25 to $2. The analyst believes the company’s “limited” liquidity, relatively high cost structure, dilution from capital increases and “intense” competition should continue to weigh on the stock price.

Top 5 initiations:

• Mizuho started interviewing last night. wolf speed (WOLF) Rating: Neutral, price target: $30. The silicon carbide market is growing at an estimated 30% annually, and competition from new and existing suppliers in the US, Europe, and China is likely to put supply, price, and margin pressure on the slowing electric vehicle market. Yes, analysts told investors in a research note.

• Wedbush began reporting on the following last night. Ovid Therapeutics (OVID) has an Outperform rating and a $8 price target. Analysts believe that small molecule central nervous system drugs have advantages when targeting specific disease states.

• Oppenheimer began reporting on Vertive Holdings (VRT) has an Outperform rating and a $96 price target. The company values ​​the company as a leading AI infrastructure company that delivers sustainable competitive differentiation in data center power and thermal management, with growth and wallet share growth associated with increased compute density. , analysts told investors in a research note.

• Mr. Leerink began his interview with adelix (ARDX) has an Outperform rating and a $14 price target.

• Brookline began reporting on immune system (IMUX) Rating is “Buy” and price target is $10. The company says IMU-838 is more potent and has an improved safety profile compared to currently available treatments.